Sanofi profit growth beats market view on early start of vaccine sales
French drug maker Sanofi on Friday posted stronger earnings growth than analysts had expected in the third quarter, boosted by an earlier-than-anticipated start of the vaccination season. Quarterly business operating income,
Sanofi Profit, Sales Beat Estimates
The French pharmaceutical company posted better-than-expected earnings and sales in the third quarter, boosted by earlier-than-anticipated flu and respiratory syncytial virus vaccine purchases.
Dengue is spreading and Sanofi is pulling the US market’s only vaccine. What’s next?
As Sanofi prepares to halt U.S. marketing of its dengue vaccine in 2026, locally acquired infections in the country are raising alarms.
Sanofi Q3 earnings beat market view, boosted by vaccine sales
French drug maker Sanofi on Friday posted stronger earnings growth than analysts had expected in the third quarter, helped by earlier-than-anticipated sales of seasonal vaccines.
Sanofi shares rise as Q3 results beat forecasts on vaccines and Beyfortus sales
Investing.com -- Sanofi (EPA: SASY) shares rose on Friday after the pharmaceutical giant posted better-than-expected third-quarter results, buoyed by strong vaccine revenues and robust early sales of Beyfortus, its respiratory syncytial virus treatment.
Sanofi Reports Higher Profit, Lifted by Early Sales of Vaccines
Sanofi’s profit rose on demand for its flu vaccines and a shot for a common respiratory virus, as well as further growth in its blockbuster skin and asthma therapy Dupixent.
Business Times22m
Sanofi profit lifted by early vaccine sales, Dupixent growth
Sanofi profit rose on demand for seasonal vaccines and further growth in its blockbuster skin and asthma therapy Dupixent.
Sanofi in Exclusive Talks With CD&R Over Sale of $17 Billion Opella
PARIS (Reuters) -French drugmaker Sanofi said on Monday it had entered exclusive talks to sell a 50% controlling stake in its ...
Sanofi Q3 Profit Rises - Quick Facts
French drug major Sanofi (SNYNF, SNY) reported third quarter net income attributable to equity holders of the company of 2.82 billion ...
Sanofi Pursues Sale Of Painkiller After Political Controversy
Sanofi confirmed on Monday plans to sell a controlling stake in its over-the-counter unit to a US investment fund, ...
Sanofi Expected to Report Higher Sales; Capital Allocation in Focus -- Earnings Preview
SALES FORECAST: The Paris-based group's sales are forecast at 12.63 billion euros, according to Visible Alpha. That compares with 11.96 billion euros for the same period the year before. As of ...
Regeneron, Sanofi announce presentation of Dupixent Phase 3 data in CSU
Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) will present data from the Phase 3 LIBERTY-CUPID Study C evaluating the investigational use ...
2minutemedicine.com2d
Sanofi’s Sarclisa approved as first-line for transplant-ineligible multiple myeloma patients
Sarclisa in combination with the VRd regiment was superior to VRd alone in improving survival in stem cell transplant ...
Sanofi Deal Jitters Imperil Stock’s Big Rebound
The French drugmaker on Monday announced progress on a deal to sell 50% of its over-the-counter division to Clayton Dubilier ...